Our oral closing statement highlights 5 key concerns - however, further details will be explored in depth in our later written submissions.
1: Therapeutics programme - wasn't good enough!
1/
The immunosuppressed were left behind.
2/
What could we have done better?
Dame Kate Bingham is an independent and trusted voice. She has no reasons to defend decisions on therapeutics that weren't the right ones.
3/
Bingham felt
"the government was following a very clear 2-tiered strategy, where CV immunocompromised patients were [.] deprioritised"
"[it] was manifestly wrong, both ethically and morally."
"We did not follow the [goal to] protect the whole population."
4/
It was *cheaper* to let those Clinically Vulenerable people shielding at home without an exit plan.
Then if they were infected to treat them with drugs [which they struggled to access].
5/
Chair of the Antivirals Taskforce, Eddie Gray, was frustrated with the funding approval process for oral antivirals - both the delays and the significantly lower purchase volume than recommended.
6/
Sir Sajid Javid said that by the time he took over, the focus was on vaccines, with less interest on antivirals.
Unlike vaccines, which had an almost unlimited budget, antivirals had no budget - purchase needed Treasury approval, where the clinical case was then questioned.
CVF is concerned that this masks the true picture.
Founder @lara_wong reminded us that some therapeutics, like Paxlovid, are unsuitable for many CV people due to interactions with medications they commonly take.
9/
We need a diverse portfolio of vaccines and antivirals for broader access.
No prophylactic (pre-treatment) has been purchased.
Had the same creativity and appetite for risk been applied to therapeutics as to vaccines, things might have been different.
10/
Sir Chris Whitty stated that antivirals are an area where we are much weaker compared to vaccines, antibodies, and antiparasitics.
He also mentioned there would be a "niche" benefit to the procurement of Evusheld... more on this to come!
11/
2: Access to Antivirals
The system to access therapeutics didn't and doesn't work.
It is significantly more restrictive than 'flu antivirals.
12/
If we can have take away food delivered in 20 minutes, why canβt we deliver life-saving medication just as fast?
13/
CVF reported that the antiviral triage system felt like the Goldilocks story. People were either:
β Too ill
β Not ill enough
Yet antivirals work best when given early, not delayed.
14/
Simply pre-flagging Clinically Vulnerable people would remove barriers and ensure faster, easier access to antivirals.
If we can get a curry delivered to our door in 20 minutes - we should be able to do the same for life-saving medication.
15/
3: Priority vaccination
Vaccination was a huge success overall.
However, many Clinically Vulnerable (Group 6) individuals faced significant confusion over their eligibility, risking them falling through the gaps in the system.
16/
Clinically Vulnerable people who donβt qualify for spring boosters will be blocked from accessing vaccines this autumn, stripping protection from millions who remain at risk from Covid.
17/
Vaccination centers were overcrowded and lacked proper ventilation.
Drive-thru centres were a great example of a safer alternative.
Improvements are essential to protect the Clinically Vulnerable - now!
18/
4: Children's Vaccines
The risk to children impacts Clinically Vulnerable households.
Media suggested children werenβt at risk, but some were - and some tragically died. Itβs vital to acknowledge this reality.
19/
There was a delay in decisions on children's vaccines. When offered, the message was vague and non-urgent, rather than engaging families.
This led to lower uptake and overlooked Clinically Vulnerable households. More consideration was needed.
20/
5: Evusheld
Evusheld was a missed opportunity for a very vulnerable group - the immunosuppressed.
We disagree with Sir Chris Whitty and JVT, who suggested it became less important once vaccines were effective. The reality is, vaccines didnβt protect them!
21/
Dame Kate Bingham said the vaccine rollout doesnβt protect those without an immune system.
Clive Dix cited *cost* as the reason Evusheld wasnβt purchased.
Chris Whitty called it "niche" use - but 1 in 38 people is hardly niche.
22/
Conclusion:
πTherapeutics poor relation of vaccines
πThe system for accessing antivirals doesnβt work
π Healthcare ventilation needs improving
π Vaccination of children = missed opportunity
π Evusheld = missed opportunity
23/
Theme:
πClinically Vulnerable were overlooked
πTheir needs underappreciated
πAnd voices not heard
24/
Clinical Vulnerability must be recognised under the Equality Act to embed their protection in law and decision-making, ensuring they are not relegated to the second-tier of a two tier system again.
25/
If you can, please support our fundraiser
- which ends tonight at 23:59!
And don't forget to like and share. Everything helps!
β οΈEast Kent Trust failed to report their first case for 2 daysβ οΈ
Here's what you need to know.
TLDR: Peaked 13th March. No new cases since - with reporting delays, but that's even better news than it sounds.
1/π§΅ π @laurabundock @SkyNews
THE OUTBREAK IS DECLINING but understates how well that's going. π
The earliest case became unwell on 9th March, with the latest on 16th March, and the peak was 13th March.
2/
Cases take time to be confirmed and reported.
The fact that nothing new has surfaced in the data as of 23rd March - despite the reporting lag - means the real-world situation is almost certainly better than the numbers show.
Meningitis
* Important thread for those who prefer balanced and factual information *
In order to understand risk we need to break down a few things....
π¦ Risk from the bacteria
πππ Individual risk
π Environmental risks 1/
The Kent outbreak is predominantly MenB (Group B). This is a serious infection - and potentially an adapted strain - investigations are ongoing...
Bacterial meningitis is rare but more severe than viral, and up to 1 in 10 cases of bacterial meningitis in the UK is fatal.
2/
MenB isn't new. There are around 300 cases of MenB per year in the UK, even with vaccination programmes.
What's unusual is the cluster - multiple cases linked to a single location in a short window. It has now spread to a student at a second university in Canterbury, Kent. 3/
UK COVID INQUIRY - CVFπππ
@AdamWagner1 Closing Submissions
The Covid Inquiry has good ventilation protocols (as advised by CVF at the start of the Inquiry) including HEPA filters.
Under 1000ppm is therefore the safe threshold ( but without it would be under 800ppm).
1/
We need to understand airborne transmission in order to make all indoor environments safer for everyone, and especially for Clinically Vulnerable people.
2/
The need for Clinically Vulnerable people to have:
CVF were concerned that many older people, who were at high risk, were not supported to shield - which included advice on how to stay safe, as well as food deliveries and community outreach.
π¨ NEW DfE GUIDANCE
- VENTILATION & AIR QUALITY -
Clean air matters - especially for #ClinicallyVulnerable children, staff and families. This is an important recognition that airborne transmission is preventable.
1/
But the proposed COβ thresholds are too high. 800ppm should be the upper limit - not 1500ppm. By 1500ppm, air is already significantly rebreathed. Thatβs not a precautionary standard for children, let alone those at higher risk.
If weβve learned anything from the pandemic, itβs that minimum compliance is not the same as safety. #ClinicallyVulnerable pupils cannot βchooseβ lower exposure if the baseline standard is poor.
3/
We would encourage you to watch @lara_wong 's inquiry evidence in full.
However, out amazing team have clipped these extracts for you!
1/
CVF's Survey
In the summer of 2025, CVF gathered in depth survey evidence about the impacts of the pandemic on CV households - which has now been shared multiple times to inquiry experts and others.
2/
People were commonly told that
"They should hurry up and die so that they could get their lives back."